Protein Assays Market to Witness Widespread Expansion During 2020-2027

 Market Research Future (MRFR) speculates that the global protein assays market is likely to register 10.8% CAGR during the forecast period (2017-2023). Use of protein assays for early diagnosis of cancer is estimated to favor the market growth. Protein assay is referred to as an analytical technique which is generally used to measure the concentration of protein in a solution and is one of the most extensively used processes in life science studies. The technique is used to detect the presence of protein in a sample. There are several types of assays available in the market which differ from one another based on principle, sensitivity, and methodology.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5091 

Market Potential and Pitfalls

With the use of protein assays for early diagnosis of HIV and cancer have significantly reduced the mortality and morbidity of the disease. Protein assays are facile, cost-effective, and reproducible, which fuels its demand over the assessment period. Lowry, Bradford, UV spectroscopic, and BCA are some of the commonly used protein assays. The use of protein assays in drug discovery and development and disease diagnosis is encouraging the pharmaceutical and biotechnological sectors to invest in research and development activities. Such factors are estimated to propel the propel assays market growth throughout the estimated period. Major market giants launch several new biomarker identification systems which create opportunities for the protein assay market globally. For instance, Gyros Protein Technologies AB had launched a new version of its anti-drug antibody solution in June 2017 for the immunogenicity market. With the emergence of the solution, the customers can automatically run the assays by using fewer volumes of patient reagents and samples in a time-efficient manner.

The market’s course is chiefly directed by rising investment by the biotech and pharmaceutical companies in R&D activities coupled with the increased funding by governments across countries for proteomics research. Moreover, the presence of a huge number of players is fostering the growth of protein assays across the globe.

On the contrary, high infrastructure cost, low research and development, insufficient trained resources, and strict regulatory framework are some of the top barriers considered to vitiate the market growth throughout the appraisal period.

Global Protein Assays Market: Segmental Analysis

The global protein assays market has been segmented on the basis of application, type, technology, product, and end-users.

By mode of type, the global protein assays market has been segmented into test strip-based assays, copper-ion-based assays, dye-binding assays, and others.

By mode of application, the global protein assays market has been segmented into drug discovery, diagnosis, protein purification, and others.

By mode of product, the global protein assays market has been segmented into instruments, reagents & kits, and others.

By mode of technology, the global protein assays market has been segmented into fluorescence-based protein assays, colorimetric-based protein assays, and absorbance-based protein assays. Among these, the absorbance-based protein assays segment is predicted to dominate the market.

By mode of end-users, the global protein assays market has been segmented into academic institutes, hospitals & diagnostic centers, pharmaceutical & biotechnology companies, and others.

Regional Insights

Geographically, the protein assays market span across regions namely, Europe, Americas, Asia Pacific, and the Middle East & Africa.

Considering the global scenario, the American region is likely to dominate the global market mainly due to the presence of North America. The North American region is estimated to occupy the largest share in this region owing to the presence of strong regional economics, research and development base, and high emphasis on wellness and disease prevention by the governments.

The European region is considered to expand at a rapid pace and is likely to retain its growth in the coming years. The growth is credited to the increasing investment in several governments and private funded R&D programs. Also, the high spending on biotechnology and the pharmaceutical industry is triggering the demand for protein assays in this region.

The Asia Pacific region is presumed to register a significant growth owing to the presence of nations such as India, Japan, and China. The healthcare expenditure in this region has increased due to the growing affluence of the population coupled with the extension of state health care programs. Also, nations like South Korea and China are striving hard to develop their biotechnology sector for better diagnosis purposes. Such factors are highly fueling the market growth in this region.

Competitive Dashboard

The prominent players operating the global protein assays market are Promega Corporation (U.S.), PerkinElmer Inc. (U.S.), Abcam plc (U.S.), Lucigen Corporation (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), New England Biolabs (U.S.), GE Healthcare (U.S.), Takara Bio Inc. (Japan), Thermo Fisher Scientific (U.S.), Cell Signaling Technology Inc. (U.S.), Bio-Techne (U.S.), QIAGEN (Germany), Bio-Rad Laboratories Inc. (U.S.), Lonza Group Ltd. (Switzerland), Illumina Inc. (U.S.), BioVision Inc. (U.S.), Merck KGaA (Germany), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/protein-assays-market-5091 

Hypotonia Market Trends Analysis Research Report 2020-2027

 The global hypotonia market is expected to grow at a CAGR of 5.8% during the forecast period.

Hypotonia is a medical condition in which babies are born with a ‘floppy’ head, owing to the fact that they have less to no control over their neck muscles. This condition has become increasingly prevalent in recent times, owing to the comparatively unhealthy lifestyles that mothers are exposed to. Not only are the environmental conditions such as the severe pollution, a cause for hypotonia, but the lifestyle of women where they are exposed to alcohol, tobacco, and harmful drugs, a reason for the prevalence of the increasing incidence of hypotonia. The global hypotonia market is majorly driven by the growing cases of hypotonia in current times, while other factors driving the growth of the market are the increasing investments towards research and development projects towards the introduction of advanced treatment methods to provide babies suffering from hypotonia better-living standards and aid.

However, the currently limited availability of facilities and higher cost of treatment is expected to hinder the market growth during the prediction period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4949 

Segmental Analysis

The global hypotonia market is segmented based on types, diagnosis, treatment, and end-user.

On the basis of the types of hypotonia in the market, it is segmented into acquired hypotonia and congenital hypotonia.  

On the basis of diagnosis methods available in the market, it is segmented into assessment of cerebrospinal fluid, blood tests, metabolic panel tests, computerized tomography or CT scan or magnetic resonance imaging (MRI) scan, electroencephalogram physical examination, genetic testing, electromyography, muscle biopsy, evaluation of thyroid hormone, nerve conduction velocity, and others.

On the basis of treatment,the hypotonia market is segmented into drugs, occupational therapy, physiotherapy, speech and language therapy, and others. Drugs are further segmented into physostigmine, neostigmine, and others.

On the basis of the end-user, it is segmented into research laboratories, hospitals & clinics, and others.

Regional Analysis

The Americas, that is, north and Latin America, are expected to dominate the global hypotonia market due to well-established technology, high health care spending, growing patient population, and growing government support for research & development activities. Also, the increase in R&D activities that are likely to take place in the forecast period, and the presence of key players have driven the growth of the hypotonia market in this region over the review period.

Europe is assessed as the second largest market share in the global hypotonia market due to government support for research & development activities for the treatment options and accessibility of funds for research. This is likely to continue to fuel the European market for hypotonia over the forecast period. The developed economies of the region, such as Germany and France, are also expected to  increase investments in the healthcare sector and are likely to focus more on hospital infrastructure.

The Asia Pacific is the fastest growing hypotonia market due to the presence of rapidly developing healthcare technology, high healthcare expenditure, and huge patient population in the region. Furthermore, the ever-increasing patient population in countries like India, Japa, and South Korea are possible to develop as the fastest-growing markets for hypotonia across the globe. Also, growing demand for quality medical devices in the healthcare sector is expected to lead the usage of progressive equipment, which, in sequence, may surge the market growth in this region.

On the other hand, the Middle East & Africa holds the smallest market share of the hypotonia market due to low availability of expenditure, and deprived political conditions in certain regions of  Africa along with limited medical facilities.

Key Players

The key players identified in the market are EnteroMedics Inc. (U.S.), LivaNova PLC (U.K), ImThera Medical (U.S.), ElectroCore Medical LLC (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), NeuroMetrix, Inc.(U.S.), and Inspire Medical Systems, Inc.(U.S.), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hypotonia-market-4949 

Hematology Diagnostics Market size in terms of volume and value 2020-2027

 Market Highlights

The renewed emphasis on health and wellness has prompted an increased focus on blood-related disorders as well. Market reports connected with the healthcare industry have been presented by Market Research Future which makes reports on other industry verticals that aims to analyze the current market scenarios better.  The market is set to profit from the positive CAGR in the market during the forecast period.

The increased prevalence of blood-related disorders is motivating the expansion of the hematology diagnostics market. Moreover, the development in the detection and diagnostic methods has improved the growth of the market for hematology diagnostics. The increased involvement of genetic diseases in blood-related ailments is projected to fuel the development of the hematology diagnostic market in the coming years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6262 

Segmental Analysis:
The segmental analysis of the hematology diagnostics market is segmented on the basis of tests, product type, and end-user. By product type, the hematology diagnostics market is segmented into flow cytometers, and consumables. The tests segment is additionally segmented into leukemia/lymphoma phenotyping, hemoglobinopathy, anemia, hematology pathophysiology, complete blood count (CBC) and others. Based on end-users, the market is segmented into ambulatory surgical centers, diagnostic laboratories, hospitals and clinics, academic institutes and others.    

Detailed Regional Analysis:
The regional analysis of the hematology diagnostics market states that the North American region dominates the market due to the mounting incidence of blood diseases. The presence of the primary market players within the region is influencing the market growth. Factors such as growing healthcare expenditure, technological improvements within the population are driving the market development in this region. The European region is the subsequent market contender in the global hematology diagnostics market due to the growing hematology research within this region. The growing hematology research and government initiatives within this region are influencing the development of the hematology diagnostic market in this region.

The Asia Pacific region was recognized as the quickest rising region for the hematology diagnostics market globally in 2017. The market is projected to observe considerable development due to the intensifying commonness of blood disorders and genetic diseases. The predisposition of individuals in the region to genetic disorders due to marriages to blood relatives or marrying within the same community, ethnicity, caste, etc. The Middle Eastern and African region controls the smallest stake in the hematology diagnostics market globally owing to the incidence of strict government policies and deprived economies. Though, the market is projected to observe growth owing to increased investments by private market players in the Middle East. Moreover, the increasing incidence of genetic blood disorders and expanding government initiatives to develop the healthcare sector within the region is expected to contribute to the market’s growth.

Competitive Analysis:
The growth of the market is moving in a favorable direction due to new product launches or rising gross revenue of the players in the market. Significant reductions in administrative costs are inducing further expansion of the market. The vertical additions and product tactics of the market are boosting the potential of the market players. The development of a robust value chain is further motivating the development of the market. The strategic goals intended for the market are reinforced due to favorable product differentiation carried out by market competitors.  Increased adaptability of market players to new market trends and customers inclinations are lifting the growth curve of the market and will continue do so in the forecast period. The successful implementation of strategies is expected to motivate the market in the coming years.

The central contenders in the hematology diagnostics market globally are Ortho Clinical Diagnostics (US), Danaher (US), Siemens (Germany), Boule Diagnostics (Sweden), HORIBA (Japan), Abbott Laboratories (US), EKF Diagnostics (UK), Bio-Rad Laboratories (US), BioSystems (Spain), Sysmex (Japan), Diatron (Hungary), Nihon Kohden (Japan), Drew Scientific (US), Mindray (China), and Roche (Switzerland), and other.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hematology-diagnostics-market-6262 

Global Pharmacovigilance Market size and forecast, 2020-2027

 Market Highlights

According to MRFR analysis, Pharmacovigilance Market is expected to register a CAGR of 14.1% during the forecast period of 2019 to 2025 and accounts for USD 4321.86 Million 2018.

Pharmacovigilance supports safe and appropriate use of drugs by identifying risk factors for the development of adverse drug reactions (ADR), promoting the detection of previously unknown ADR and their interactions with known ADR.

The market is dominated by numerous established players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, on May 16, 2019, Accenture launched INTENT to improve the continuity and flow of data across life sciences enterprises, supporting the delivery of ground-breaking treatments for patients.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8451 

Segmentation

The Global Pharmacovigilance Market has been segmented based on the clinical trial phase, service provider, type, and end-user.

The market, based on the clinical trial phase, has been divided into phase IV, phase III, phase II, phase I, and pre-clinical. Phase IV segment dominated the pharmacovigilance market as adverse drug reactions are majorly detected in this phase. Whereas, phase III is expected to witness the fastest growth.

The global pharmacovigilance market has been segmented, on the basis of service provider, into in-house and contract outsourcing. Contract outsourcing dominated the global pharmacovigilance market and expected to witness the fastest growth. Contract manufacturing serves multiple customers and thus can acquire raw materials at a reduced cost, benefiting from the economies of scale.  

The market, based on type, has been divided into spontaneous reporting, cohort event monitoring, intensified ADR reporting, targeted spontaneous reporting, and EHR mining. The spontaneous reporting held largest market share in 2018. Spontaneous reporting is a passive approach to pharmacovigilance as it entirely relies on the motivation of individuals to report suspected ADRs to a local or national pharmacovigilance center.

In terms of end-user, the global pharmacovigilance market has been segmented into hospitals, research organizations, pharmaceutical companies, and others. Hospitals take up the largest share due to an increase in the number of hospital admissions due to ADRs.

Key Players

Some of the key players in the Global Pharmacovigilance Market are Accenture (Ireland), ArisGlobal (US), BioClinica (US), Capgemini (France), Conquest Group BV (Netherlands), Cognizant (US), IBM Corporation (US), ICON PLC (Ireland), IMEDGlobal (US), ITClinical (Portugal), Laboratory Corporation of America Holdings (US), PAREXEL International Corporation (US), TAKE Solutions Ltd (India), United BioSource Corporation (US), and Wipro Ltd (India).

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the high spending by the pharmaceutical industry. The pharmacovigilance market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European Pharmacovigilance market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Pharmacovigilance market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing prevalence of chronic conditions and rising cases of ADRs and medication errors, the market in Asia-Pacific is expected to be the fastest-growing. The pharmacovigilance market in the Middle East & Africa has been divided into the Middle East and Africa.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pharmacovigilance-market-8451 

Global Anti-Fungal Treatment Market size and forecast, 2020-2027

 The global anti fungal treatment market is expected to register a CAGR of6.35% during the forecast period and is expected to hit USD 25,764.67 million by 2027.

Fungi are defined as microorganisms that can stay alive in a wide array of environments. Fungi can lead to diverse infections in the human body ranging from superficial skin to systemic that enters the body through inhalation. These infections occur in the human body, usually due to high exposure to unhygienic environments of fungus or due to low immune systems.

The most common fungal infections include ringworm, athlete’s foot, and fungal nail infection Furthermore, the increasing incidence of infections such as mucormycosis, candidiasis, and others are expected to propel market growth. Furthermore, anti fungal drugs restrict fungal microorganisms from growing on the host cell and eliminate the occurrence of fungal infection. Thus, the availability of diverse anti fungal drugs for the treatment of fungal infection and over-the-counter drugs for the treatment of dermal infection is positively influencing the anti fungal drug market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/10602 

Segment Analysis

The global anti fungal treatment market has been divided based on drug class, therapeutic indication, pathogen, and end user.The market, based on drug class, has been segregated into azoles, echinocandins, polyenes, allylamines, pyrimidines, and others.

Based on therapeutic indication,the anti fungal treatment market has been divided intotherapeutic indications, has been segmented into systemic, candidiasis, cryptococcosis, prophylactic use of anti fungals, and coccidioidomycosis.

Based on pathogen, the anti fungal treatment market has been divided into Candida, Aspergillus, Cryptococcus, Coccidioides immitis, Zygomycetes, Trichophyton, others.On the basis of end user, the market is bifurcated into hospitals and clinics, dermatology clinics, and others.

Regional Analysis

The global anti fungal treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa. The 40.97% market share of the Americas can be attributed to the high prevalence of anti fungal diseases, research spending, and the rapid adoption of advanced treatment in the region. The availability of a large research budget is anticipated to increase the grants for researchers to develop novel products for the anti fungal treatment market.

Europe is projected to exhibit significant growth during the forecast period due to a higher number of patients and the availability of diagnostic and treatment facilities in the region.The accessibility to advanced treatment facilities, rising government initiatives to promote research to find a cure to the increasing number of cases, and growing healthcare expenditure are driving the growth of the anti fungal treatment market in the region.

Asia-Pacific is expected to be the fastest-growing regional market in anti fungal treatment, mainly due to increasing R&D funding by developing countries such as China and India for the availability of basic treatments.The market for anti fungal treatment is growing at a significant rate in the Middle East & Africa due to the increasing number of companies and subsidiaries in the region offering treatment options.

Key Findings of the Study

• The global anti fungal treatment market was valued at USD 15,835.52 millionin 2019 and is projected to register a CAGR of6.35% during the assessment period.
• The Americas accounted for the largest share of the global market due to the rising prevalence of anti fungal diseases, research spending, and the rapid adoption of advanced treatment in the region.
• Based on drug class, the azoles segment accounted for the largest market share of 41.7% in 2019
• On the basis of ther apeutic indication, the candidiasis segment is expected to register the fastest growth at a CAGR of 6.64% during the forecast period
• By pathogen, the candida segment accounted for the largest market share with a value of USD 8,176.20 million in 2019
• Based on end user, the hospitals & clinics segment accounted for the largest market share with a value of USD 7,300.92 million in 2019
• Pfizer Inc. (US), Novartis International AG (Switzerland), Sanofi S.A.(France), Merck KGaA (Germany), Bayer AG (Germany)are the key market players.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/anti-fungal-treatment-market-10602 

Central Nervous System Biomarkers Market to Witness Widespread Expansion During 2020-2027

 According to MRFR analysis, the global CNS biomarkers marketis expected to register a CAGR of~13.0%from 2021 to 2027and hold a value of over ~USD 7,500 million by2027.

The global CNS biomarkers market is driven by several factors, such astechnological advancements, an increase in the use of biomarkers inthe diagnosis of neurodegenerative diseases, increasing research and development, and successful clinical trials.According to Alzheimer’s Disease International, in 2020, over 50 million people have dementia, where CNS disorders help in the diagnosis and prognosis of the disorders. Furthermore, recent technologies such as genomics and proteomics, and imaging technologies, several new biomarkers are being developed.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9140 

The key players are involved in new product launches, strategic agreements, and joint ventures to augment their market positions. For instance, in September 2020, Siemens Healthineers (Germany) announced a strategic collaboration with Novartis Pharma AG (Switzerland) for biomarker development for Multiple Sclerosis. Furthermore, new product approvals by the FDA are supplementing the market growth. For instance, in May 2019, the N170 CNS biomarker letter of intent was accepted by the FDA for autism spectrum disorder, submitted by Roche (Switzerland) for approval.

Regional Analysis

North America is expected to dominate the CNS biomarkers market in 2021, owing to the growing geriatric population, the adoption of the latest technologies for CNS disorder treatment, and key industry players across the region. According to the US Census Bureau, the country .constitutesaround 34% of the population aged 65 andolder; this number has increased by 3.2% over a year. Among the different regions in the Americas, Maine ranks first with the highest geriatric population. This is increasing the demand for CNS biomarkers across the region sinceagingincreases the risks of brain disorders and other CNS disorders. Furthermore, companies and research institutes are constantly innovating and discovering new technologies and biomarkers. This is supported by the presence of leading key players within the region as well as increasing R&D expenditure. For instance, as of August 2020, USD 23.1 million was funded for brain-related clinical and cancer control research in the US, according to the American Cancer Society.     

In Europe, the increase in demand for personalized/precision medicine and the prevalence of neurological diseases in Europe are driving the CNS biomarkers market in the region. According to the report published in October 2020, in Europe, neurological disorders ranked third after cardiovascular diseases and cancer. Furthermore, another report published in July 2020 by King’s College London, by 2047, there will be 2.5 million cases of stroke in Europe, which is a 23% increase from 2017 data.

Asia-Pacific is expected to be the fastest-growing regional market in the forecast period due to factors such asa large customer base, high prevalence of CNS disorders, and improving healthcare infrastructure. China accounts for the highest number of stroke cases in the world, with 354 cases per 100,000 people in 2016, according to a report published in The Lancet in March 2019; this shows the immense application of CNS biomarkers in the region.

The rest of the world includes the Middle East, Africa, and Latin America. These regions are also facing an increase in neurological disorders, which is driving the CNS biomarkers market. For instance, according to a report from Alzheimer’s Disease International 2020, an estimated 6% of the 15 million older people (above the age of 50 years) in Brazil.  

Segmentation

The global CNS biomarkers market has been segmented into type, application, and end user.

By type, the market has been segregated into safety biomarker,efficacy biomarker, validation biomarker, and others. The safety biomarker segment is expected to hold a considerable share of the market in 2020due to its importance in clinical trials. The majority of the clinical trials fail due to safety and toxicity issues.

Based on application, the global CNS biomarkers market has been classified intodrug discovery & development, personalized medicine,and others. Personalized medicine witnessed high growth as the emphasis on personalized medicine increases due to more effectiveness and risk of minimal side effects than present treatments.

Based on end user,the CNS biomarkers market is classified intodiagnostic labs, hospitals&clinics and research centers. Diagnostic Labs held asignificantmarket share in 2020 due toincreasing neurological disorders across the globe and the need for diagnosis for the same.

Key Players

Some of the key players in the global CNS biomarkers marketareThermo Fisher Scientific (US), Merck & Co. (US), AbaStarMDx Inc. (US), Abiant, Inc. (US), Avacta Group plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc. (US), and Acumen Pharmaceuticals Inc. (US) amongothers.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/central-nervous-system-biomarkers-market-9140 

Global Companion Diagnostics for Oncology Market size and forecast, 2020-2027

 Global Companion Diagnostics for Oncology Market is expected to register a CAGR of 22.57% during the forecast period and is expected to hit USD 5,064.17 Million by 2027.

A companion diagnostic is an in vitro diagnostic medical kit. Through this test, healthcare professionals can determine whether a particular therapeutic product is effective for the patient or possess any serious side effects or risks. The key factors driving the market growth are increasing R&D and drug-diagnostic co-development, growing preference for personalized medicine, increasing global incidence of cancer, and increasing product approvals by major players. However, the lack of reimbursement in developing regions may hamper the market growth. The entry of market players in emerging economies creates growth opportunities for the companion diagnostics for the oncology market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/10422 

Major market players are focusing on various growth strategies such as product launches, product advancements, and business expansions to cater to the growing need for personalized medicine. These product launches and business expansion drive the growth of the companion diagnostics for oncology market. For instance, in March 2020, Thermo Fisher signed a strategic agreement with Janssen Services to co-develop a companion diagnostic product related to oncology, which will support clinical trial enrollment globally. Similarly, in March 2019, Roche launched the Ventana PD-L1 (SP142) Assay in Europe as the first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq. Furthermore, in March 2019, Roche received the US FDA approval for its Ventana PD-L1 (SP142) assay approved as the first companion diagnostic to identify triple-negative breast cancer patients eligible for the treatment with Tecentriq in combination with Abraxane.

Segment Analysis

Global Companion Diagnostics for Oncology Market has been segmented based on products & services, technology, indication, and end user. The market, on the basis of products & services, has been segmented into assays, kits & reagents and software & services.

Based on technology, the global companion diagnostics for oncology market is segmented into polymerase chain reaction (PCR) and next-generation sequencing (NGS). The global market, on the basis of indication, has been segmented into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others.

Regional Analysis

Global Companion Diagnostics for Oncology Market, based on region, is segmented into four main regions, including the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is accounted for a major market share in 2019, whereas Asia-Pacific is projected to be the fastest-growing regional market during the forecast period.

In the global companion diagnostics for oncology market, the Americas held the largest share of 37.3% in 2019. The market growth in the Americas is due to the high prevalence rate of cancer and rising healthcare expenditure. According, to the National Institutes of Health, it was estimated that 1,735,350 new cases of cancer were diagnosed in the US in 2018. Europe acquired the second-largest market share in 2019. The Europe market is expected to register a sturdy growth rate during the forecast period due to the presence of a large number of companies, growing research and development activity to develop targeted drug therapy for a cancer patient, and the rising per capita income increasing the preference for personalized medicine. According to the European Journal of Cancer, there were around 3.9 million new cases and 1.9 million deaths from cancer in Europe in 2018. The increasing cancer population supports market growth in this region.

Asia-Pacific is anticipated to be the fastest-growing regional market during the forecast period. The rapid growth of the Asia-Pacific market is due to the growing number of cancer patients and rising presence of market players. According to the Global Cancer Observatory, around 1,157,294 cases of cancer were reported in India in 2018. Additionally, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are expected to drive the growth of the regional market. The Middle East and Africa accounted for the least market of USD 82.64 million in 2019. The companion diagnostics for oncology market in countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing cancer cases, rising drug discovery, and increasing preference for personalized medicines. Also, the growing number of hospitals, research laboratories, and increasing investment by healthcare companies in this region drives the growth of CDx in the Middle East & African countries.

Key Players

MRFR recognizes the following companies as the Key Players in the global Companion Diagnostics for Oncology Market— Agilent Technologies Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), BioMérieux SA (France), Foundation Medicine (US), Archer Dx (US), Qiagen (Germany), Thermo Fisher Scientific Inc. (US), and Amoy Dx (China) and Abbott Laboratories (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/companion-diagnostics-oncology-market-10422